Banner
Home

The Women's Libido Pill Is Back, and So Is the Controversy Print E-mail
Written by Cynthia Koons | Bloomberg via Yahoo! Finance   
Tuesday, 19 June 2018 17:09
 
This past January, when Cindy Eckert got back the keys to her old office in Raleigh, N.C., she walked into a time capsule. An empty water glass still sat on the receptionist's desk. Piles of marketing materials were gathering dust. Boxes with three-year-old FedEx labels had never been shipped. It was the first time Eckert had entered the office since she sold-and was then pushed out of-her company, Sprout Pharmaceuticals Inc. She and her then-husband started the company to bring to market the first drug to enhance female sexual desire. Since that moment, the story of Addyi, the pink pill, has been frozen in time.
 
Read More

Last Updated on Tuesday, 19 June 2018 17:22
 
Trump administration wants to gut pre-existing condition protections, putting GOP candidates in a bad spot Print E-mail
Written by FHI's Week in Review   
Monday, 11 June 2018 13:44
 
Mike Stankiewicz, in a Jun 8, 2018 Fierce Healthcare post, reports that the Department of Justice said this week it mostly agrees with a lawsuit (filed by 20 Republican states leaders) that claims the Affordable Care Act's individual mandate is unconstitutional since the GOP zeroed out its penalty last year. The Trump administration also said that pre-existing condition protections within the law were inseparable from the mandate and must be struck down as well, according to the author.
 
Read more in the current issue of Week in Review>> https://conta.cc/2JDU7nT
 
Last Updated on Monday, 11 June 2018 13:48
 
'End of an Era' for Chemo in Non-Small Cell Lung Cancer Print E-mail
Written by FHI's Week in Review   
Monday, 04 June 2018 16:48
 
Liam Davenport reports for Medscape on June 03, 2018 that most patients with advanced non-small cell lung cancer (NSCLC) can now avoid having chemotherapy as a first-line treatment, after a large, randomized trial showed that immunotherapy with the programmed cell death ligand 1 (PD-L1) blocker pembrolizumab (Keytruda, Merck) is effective even in patients with minimal PD-L1 expression.
 
Read more in the current issue of Week in Review>> https://conta.cc/2xDXg5G
 
Last Updated on Monday, 04 June 2018 17:30
 
Senate passes VA MISSION Act, raising concerns of privatization Print E-mail
Written by FHI's Week in Review   
Monday, 28 May 2018 14:34
 
A Fierce Healthcare article, by Tina Reed and dated May 24, 2018, informs us that the VA MISSION Act will head to the president's desk where it is expected to be signed after passing the Senate on Wednesday <5.23.18>. The $55 million reform bill would, among other things, change where veterans can receive care, create hiring incentives to bring on more VA healthcare providers and establish a commission to examine the VA's aging infrastructure, according to Ms. Reed.
 
Read more in the current issue of Week in Review>> https://conta.cc/2xi7OqY
 
Last Updated on Monday, 28 May 2018 14:37
 
Sponsor Showcase Print E-mail
Written by Sponsor   
Tuesday, 05 June 2018 00:00
 
bdo-ftl-florida-health-industry-ad-9-16 final
Last Updated on Tuesday, 05 June 2018 17:17
 


Banner
Website design, development, and hosting provided by
Netphiles